Interventions for previously untreated patients with AIDS-associated Non-Hodgkin´s Lymphoma (Q24240190)

https://api.crossref.org/works/10.1002%2F14651858.CD005419.PUB2

Clinical and virologic effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients receiving chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma: results of a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005419.PUB2

Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005419.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005419.PUB2

Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005419.PUB2

Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005419.PUB2

Chemotherapy combined with zidovudine and GM-CSF in human immunodeficiency virus-related non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005419.PUB2

Human immunodeficiency virus-related lymphoma treatment with intensive combination chemotherapy. French-Italian Cooperative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005419.PUB2

Liposome-encapsulated doxorubicin in combination with standard agents (cyclophosphamide, vincristine, prednisone) in patients with newly diagnosed AIDS-related non-Hodgkin's lymphoma: results of therapy and correlates of response

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005419.PUB2

Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005419.PUB2

Pilot trial of infusional cyclophosphamide, doxorubicin, and etoposide plus didanosine and filgrastim in patients with human immunodeficiency virus-associated non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005419.PUB2

Phase II trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group Trial (E1494).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005419.PUB2

Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005419.PUB2

Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005419.PUB2

Statistics and ethics in medical research: III How large a sample?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005419.PUB2

Statistical power of negative randomized controlled trials presented at American Society for Clinical Oncology annual meetings

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005419.PUB2

AIDS-associated non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005419.PUB2

Therapeutic approaches to AIDS-related malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005419.PUB2

Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005419.PUB2

Kaposi's sarcoma and non-Hodgkin's lymphoma following the diagnosis of AIDS. Multistate AIDS/Cancer Match Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005419.PUB2

The epidemiology of AIDS--related neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005419.PUB2

Reflections on medical oncology: 25 years of clinical trials--where have we come and where are we going?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005419.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005419.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005419.PUB2

Epidemiologic trends in HIV-associated lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005419.PUB2

Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005419.PUB2

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005419.PUB2

Non-AIDS-defining cancer in HIV-infected people.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005419.PUB2

Non-Hodgkin's lymphoma among people with AIDS: incidence, presentation and public health burden. AIDS/Cancer Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005419.PUB2

Epidemiology of non-Hodgkin lymphomas and other haemolymphopoietic neoplasms in people with AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005419.PUB2

Cancer risk in people infected with human immunodeficiency virus in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005419.PUB2

The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial. Survey of 71 "negative" trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005419.PUB2

HIV infection and lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005419.PUB2

The epidemiology of non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005419.PUB2

Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005419.PUB2

Prominent medical journals often provide insufficient information to assess the validity of studies with negative results

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005419.PUB2

Response to highly active antiretroviral therapy strongly predicts outcome in patients with AIDS-related lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005419.PUB2

AIDS-associated non-Hodgkin's lymphoma in San Francisco

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005419.PUB2

Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005419.PUB2

Infectious complications associated with immunomodulating monoclonal antibodies used in the treatment of hematologic malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005419.PUB2

Characteristics of indolent non-Hodgkin lymphoma in patients with type 1 human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005419.PUB2

Management of AIDS-related lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005419.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005419.PUB2

Systemic chemotherapy for HIV-associated lymphoma in the era of highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005419.PUB2

Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005419.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005419.PUB2

Prognosis of AIDS-related systemic non-Hodgkin lymphoma treated with chemotherapy and highly active antiretroviral therapy depends exclusively on tumor-related factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005419.PUB2

Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005419.PUB2

Statistical power, sample size, and their reporting in randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005419.PUB2

Modern management of non-Hodgkin lymphoma in HIV-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005419.PUB2

HIV: clinical manifestations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005419.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005419.PUB2

21 January 2018

Update in HIV lymphoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005419.PUB2

21 January 2018

Update on HIV lymphoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005419.PUB2

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005419.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005419.PUB2

Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005419.PUB2

Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005419.PUB2

Novel oral combination chemotherapy in the treatment of intermediate-grade and high-grade AIDS-related non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005419.PUB2

Oral combination chemotherapy in conjunction with filgrastim (G-CSF) in the treatment of AIDS-related non-Hodgkin's lymphoma: evaluation of the role of G-CSF; quality-of-life analysis and long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005419.PUB2

Treatment options of AIDS-related lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005419.PUB2

Clinical aspects and management of AIDS-related lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005419.PUB2

Human immunodeficiency virus associated lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005419.PUB2

Rituximab for HIV-associated lymphoma: weighing the benefits and risks.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005419.PUB2

Antiretroviral treatment regimens and immune parameters in the prevention of systemic AIDS-related non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005419.PUB2

The evidence-based treatment of AIDS-related non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005419.PUB2

Improving the design of phase II trials of cytostatic anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005419.PUB2

Acquired immunodeficiency syndrome-related lymphoma in the era of highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005419.PUB2

Acquired immunodeficiency syndrome-associated cancers in Sub-Saharan Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005419.PUB2

Absolute level of Epstein-Barr virus DNA in human immunodeficiency virus type 1 infection is not predictive of AIDS-related non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005419.PUB2

Systemic non-Hodgkin lymphoma in individuals with known dates of HIV seroconversion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005419.PUB2

Acquired immunodeficiency syndrome-related lymphoma: simultaneous treatment with combined cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy and highly active antiretroviral therapy is safe and improves survival--results of the

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005419.PUB2

7 January 2021

Are Phase 2 screening trials in oncology obsolete?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005419.PUB2

7 January 2021

Infusional CDE with rituximab for the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: preliminary results of a phase I/II study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005419.PUB2

7 January 2021

Update on the Pathogenesis, Diagnosis, and Therapy of AIDS-related Lymphoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005419.PUB2

7 January 2021

[Non Hodgkin's and Hodgkin's lymphomas and HIV: frequency, outcome and immune response under HAART; Clermont-Ferrand University Hospital, 1991-2003]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005419.PUB2

7 January 2021

AIDS-related lymphoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005419.PUB2

7 January 2021

[GESIDA/PETHEMA guidelines for the diagnosis and treatment of lymphomas in HIV-infected patients]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005419.PUB2

7 January 2021

Why "underpowered" trials are not necessarily unethical

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005419.PUB2

7 January 2021

Phase I/II trial of filgrastim (r-metHuG-CSF), CEOP chemotherapy and antiretroviral therapy in HIV-related non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005419.PUB2

7 January 2021

Prospective study with combined low-dose chemotherapy and zidovudine in 37 patients with poor-prognosis AIDS-related non-Hodgkin's lymphoma. French-Italian Cooperative Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005419.PUB2

7 January 2021

Rates of non-AIDS-defining cancers in people with HIV infection before and after AIDS diagnosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005419.PUB2

7 January 2021

AIDS-related malignancies

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005419.PUB2

7 January 2021

Prognostic factors in the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: analysis of AIDS Clinical Trials Group protocol 142--low-dose versus standard-dose m-BACOD plus granulocyte-macrophage colony-stimulating factor.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005419.PUB2

7 January 2021

Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005419.PUB2

7 January 2021